Healthcare Mergers & Acquisitions and Financing Panel


“Consolidation Trends and Financing Market for Life Sciences and Healthcare Services”

  • ModeratorStuart Smith '84, Co-Head and Managing Director of Healthcare Investment Banking, Credit-Suisse
  • Paul Clancy '87, Executive Vice President and Chief Financial Officer, Biogen Idec
  • Jay Galeota, Chief Strategy & Business Development Officer, President, Emerging Businesses, Merck & Co., Inc.
  • Matthew McAskin '04 (EMBA), Senior Managing Director, Evercore Partners
  • Sooin Kwon '01, Managing Director, MTS Health Partners


  • Reasons for consolidation activity of pharma and medical device companies, including unique integration challenges. Will increased focus on tax inversion deals continue?
  • What diversification/growth strategies are being pursued by major payers through use of M&A, joint ventures and partnerships?
  • Will we continue to see hospital mergers to gain scale and competitive advantage – what other acquisition targets will hospitals pursue?
  • What is the current antitrust environment in healthcare dealmaking?
  • What is the current state of the IPO and financing market for early-stage healthcare and life science companies?


Stuart Smith '84
Co-Head and Managing Director of Healthcare Investment Banking

Stuart F. Smith is a Managing Director of Credit Suisse in the Investment Banking division, based in New York. He is Global Head of Health Care within the Investment Banking Department.

Stuart joined Credit Suisse First Boston in 1999 from Alex. Brown & Sons and its successor firms, where he was a Managing Director. He has been involved in structuring numerous M&A transactions as well as effecting financings for clients across all sectors of the health care industry including: Aetna, Community Health, Express Scripts, Genzyme, LabCorp, WellPoint and Zimmer.

Stuart received an M.B.A. from the Columbia Business School, a J.D. from the University of Connecticut School of Law and a B.S. from Franklin and Marshall College.

Paul Clancy '87
Executive Vice President & Chief Financial Officer
Biogen Idec

Paul J. Clancy is the Executive Vice President and Chief Financial Officer at Biogen Idec and has served in these positions since August 2007. Mr. Clancy has also served as Senior Vice President of Finance and Vice President of Business Planning at Biogen Idec. Prior to the merger, Mr. Clancy had served as Vice President of Portfolio Management at Biogen Inc. since 2003. He joined the company in 2001 as Vice President, US Marketing. Before joining Biogen, Mr. Clancy spent 13 years at PepsiCo, serving in a range of financial and general management positions including most recently Vice President and General Manager of their Great West Business Unit. Mr. Clancy holds a Bachelor of Science degree in Finance from Babson College and a Master of Business Administration degree from Columbia Business School.

  Jay Galeota
Chief Strategy & Business Development Officer, President, Emerging Businesses
Merck & Co., Inc.

Bio coming soon.

Matthew McAskin '04 (EMBA)
Senior Managing Director
Evercore Partners

Matthew McAskin is a Senior Managing Director of the firm's corporate advisory business. Mr. McAskin is focused on advising clients in the healthcare services sector.

Mr. McAskin was most recently a Managing Director and co-head of Healthcare Services Investment Banking at Goldman Sachs. With over 17 years of banking experience at Goldman Sachs and JPMorgan, Mr. McAskin has extensive experience advising a broad array of healthcare services companies and private equity firms, and he has advised on a number of the most recent notable transactions in the hospital, managed care, HCIT, physician services and outsourced medical services subsectors.

Mr. McAskin received his BA in Economics from the University of Michigan and received MBA degrees from Columbia Business School and London Business School.

Sooin Kwon '01
Managing Director
MTS Health Partners

Ms. Kwon has been in finance since graduating from Columbia Business School in 2001 at both large (100,000+ employees) and small firms (10-50 employees) and has worked primarily in equity research and investment banking.

She is currently a Managing Director in life sciences investment banking at MTS Health Partners, L.P. where she focuses on M&A transactions and privately negotiated financings for biotech, pharma, generics, diagnostics and medical device companies. She is one of eight Managing Directors in the investment banking division and leads the West Coast office. MTS Health Partners is a healthcare-focused investment banking and private equity fund with 50 team members in New York and San Francisco.

Prior to joining MTS Health Partners, Ms. Kwon was a Principal in the Healthcare Equity Capital Markets Group at Bank of America, where she advised healthcare (services, devices, life sciences) clients on public capital markets strategy and originated and executed IPOs and other public equity financing transactions.

Before Bank of America, Ms. Kwon was an equity research analyst on both the buy-side and sell-side at Merlin Biomed Asset Management and UBS, respectively. Her research coverage included a broad spectrum of U.S. and European life science companies.

Prior to business school, she was based in London working at the Equinox Group, a pharmaceutical/biotech consulting firm, focusing on market analyses and revenue forecasts for drugs in development for multi-national biotech and pharmaceutical companies.

Ms. Kwon has an MBA from the Graduate School of Business at Columbia University and a BA from Tufts University.